| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
8-Deacetyl yunaconitine targets voltage-gated sodium channels, similar to other Aconitum alkaloids. By modulating Na⁺ channel activity, it may exert analgesic and anti-inflammatory effects. Its mechanism of action is characteristic of diterpenoid alkaloids from Aconitum species.
|
|---|---|
| ln Vitro |
In vitro, 8-Deacetyl yunaconitine has been studied for its biological activities. It is a diterpenoid alkaloid that modulates voltage-gated Na⁺ channels. Its effects are consistent with its mechanism of action as a Na⁺ channel modulator. However, specific in vitro activity data are not extensively detailed in the available literature.
|
| ln Vivo |
In vivo, 8-Deacetyl yunaconitine has the potential to exert analgesic and anti-inflammatory effects, characteristic of Aconitum alkaloids. However, specific in vivo efficacy data in animal models are not extensively detailed in the available literature. It is a research compound and is not approved for clinical use.
|
| Enzyme Assay |
In vitro Na⁺ channel binding assays for 8-Deacetyl yunaconitine are performed using membrane preparations from cells expressing voltage-gated Na⁺ channels. Radioligand binding studies employ [³H]-batrachotoxin or other suitable tracers. Membranes are incubated with varying concentrations of 8-Deacetyl yunaconitine, and bound and free ligands are separated by filtration. IC₅₀ values are calculated from competition binding curves.
|
| Cell Assay |
In vitro cell-based assays for 8-Deacetyl yunaconitine are performed using neuronal cell lines or primary neurons. Cells are cultured in appropriate media and treated with 8-Deacetyl yunaconitine at various concentrations. Na⁺ channel activity is measured using patch-clamp electrophysiology or by using fluorescent voltage-sensitive dyes. Cell viability is assessed by MTT assays.
|
| Animal Protocol |
In vivo animal studies for 8-Deacetyl yunaconitine would typically involve rodent models of pain and inflammation. The compound is administered orally or intraperitoneally. Pain responses are assessed using behavioral tests, such as the hot plate test or the formalin test. Inflammation is assessed by measuring paw edema or by histological analysis.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic properties of 8-Deacetyl yunaconitine are not extensively detailed in the available literature. As a diterpenoid alkaloid with a molecular weight of 617.73 g/mol, it is expected to have moderate oral bioavailability. It is soluble in DMSO and is typically formulated for in vivo administration.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for 8-Deacetyl yunaconitine are not widely available in public literature. As a research compound, it is intended for laboratory use only and is not for human therapeutic use. Standard safety precautions should be followed when handling this compound. The compound is supplied with a purity of ≥98%.
|
| References |
|
| Additional Infomation |
There have been reports that 8-deacetylated aconitine has been found in Aconitum transsectum and Aconitum balfourii, and relevant data are available for reference.
8-Deacetyl yunaconitine is a diterpenoid alkaloid from Aconitum forrestii. It is also known as 8-Deacetylyunaconitine. It is a research compound used to study the pharmacology of Aconitum alkaloids. This product is for research use only. |
| Molecular Formula |
C33H47NO10
|
|---|---|
| Molecular Weight |
617.727
|
| Exact Mass |
617.319
|
| CAS # |
93460-55-0
|
| PubChem CID |
137706281
|
| Appearance |
White to off-white solid powder
|
| Source |
Originated from plants: Ranunculaceae Aconitum forrestii Stapf
|
| LogP |
0.6
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
44
|
| Complexity |
1120
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
CCN1CC2(C(CC(C34C2C(C(C31)C5(CC(C6(CC4C5C6OC(=O)C7=CC=C(C=C7)OC)O)OC)O)OC)OC)O)COC
|
| InChi Key |
DHVYLCVNTWPXSI-HIUSHPNESA-N
|
| InChi Code |
InChI=1S/C33H47NO10/c1-7-34-15-30(16-39-2)20(35)12-21(41-4)33-19-13-31(37)22(42-5)14-32(38,24(27(33)34)25(43-6)26(30)33)23(19)28(31)44-29(36)17-8-10-18(40-3)11-9-17/h8-11,19-28,35,37-38H,7,12-16H2,1-6H3/t19-,20-,21+,22+,23-,24?,25?,26-,27-,28-,30+,31+,32-,33+/m1/s1
|
| Chemical Name |
[(1S,2R,3R,4R,5S,6S,8R,10R,13R,14R,16S,17S)-11-ethyl-5,8,14-trihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] 4-methoxybenzoate
|
| Synonyms |
8-deacetylyunaconitine 8-Deacetyl-yunaconitine 8-Deacetyl yunaconitine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~80.9 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.05 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (4.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6188 mL | 8.0942 mL | 16.1883 mL | |
| 5 mM | 0.3238 mL | 1.6188 mL | 3.2377 mL | |
| 10 mM | 0.1619 mL | 0.8094 mL | 1.6188 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
